241 related articles for article (PubMed ID: 32305267)
1. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
2. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Sheinfeld J
Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
5. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
[TBL] [Abstract][Full Text] [Related]
6. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
7. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
Tachibana I; Kern SQ; Douglawi A; Tong Y; Mahmoud M; Masterson TA; Adra N; Foster RS; Einhorn LH; Cary C
J Clin Oncol; 2022 Nov; 40(32):3762-3769. PubMed ID: 35675585
[TBL] [Abstract][Full Text] [Related]
8. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
[TBL] [Abstract][Full Text] [Related]
9. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
[TBL] [Abstract][Full Text] [Related]
10. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
11. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
12. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
13. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
Speir RW; Calaway AC; Einhorn LH; Foster RS; Cary C
Urol Oncol; 2020 Aug; 38(8):687.e19-687.e23. PubMed ID: 32448503
[TBL] [Abstract][Full Text] [Related]
14. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
15. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.
Tong S; Chen M; Zu X; Li Y; He W; Lei Y; Liu W; Qi L
Int Urol Nephrol; 2014 Feb; 46(2):363-9. PubMed ID: 23996573
[TBL] [Abstract][Full Text] [Related]
16. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle.
Ghandour R; Ashbrook C; Freifeld Y; Singla N; El-Asmar JM; Lotan Y; Margulis V; Eggener S; Woldu S; Bagrodia A
Eur Urol Oncol; 2020 Apr; 3(2):198-206. PubMed ID: 31272940
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
[TBL] [Abstract][Full Text] [Related]
19. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014.
Tabakin AL; Shinder BM; Kim S; Rivera-Nunez Z; Polotti CF; Modi PK; Sterling JA; Farber NJ; Radadia KD; Parikh RR; Kim IY; Saraiya B; Mayer TM; Singer EA; Jang TL
Clin Genitourin Cancer; 2020 Apr; 18(2):e194-e201. PubMed ID: 31818649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]